Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Tryp Therapeutics announces research alliance with the University of Michigan 

By Brian Buntz | July 7, 2021

Tryp TherapeuticsLa Jolla, Calif.–based Tryp (CSE: TRYP) is tapping the University of Michigan to test its TRP-8803 drug formulation against traditional oral formulations of synthetic psilocybin.

The psilocybin-based drug developer will also work with the university to compare TRP-8803 with conventional formulations of synthetic psilocybin. In particular, the university will perform pharmacokinetic analysis for blood samples from patients who received psilocybin via oral and novel delivery methods.

Additionally, Tryp expects the partnership with the University of Michigan to help advance TRP-8803 to Phase 2b clinical trials. The research alliance will explore the psilocybin-induced increase in neurophysiological complexity and psilocybin’s potential to reduce chronic central pain. The University of Michigan also will explore the impact of alternative delivery strategies of psilocybin on pain indices and insular glutamate and gamma-aminobutyric acid (GABA) levels.

Tryp has also entered into an advisory agreement with University of Michigan professor Dr. George A. Mashour regarding the initial clinical trial design for TRP-8803.

“The University of Michigan has extensive expertise in the dosing and delivery of active pharmaceutical ingredients and world-class expertise in several pain-related indications that are aligned with our interests,” said Jim Gilligan, president and chief science officer of Tryp Therapeutics, in a statement.

While the recent news focuses on TRP-8803, TRP-8802 is the company’s lead pipeline candidate. In February, the company announced that it was also entering into a partnership with Dr. Jennifer Miller of the University of Florida as the principal investigator of a clinical study to test the potential of TRP-8802 in treating eating disorder symptoms. Tryp also believes that TRP-8802 has the potential to treat fibromyalgia and chronic pain disorders.

In recent years, psychedelic compounds have emerged as promising potential treatments for various conditions in psychiatry and beyond.

In 2018, FDA gave an investigational psilocybin drug from Compass Pathways (NSDQ:CMPS) a breakthrough therapy designation for treatment-resistant depression. In addition, FDA has also granted breakthrough therapy designation to MDMA-assisted psychotherapy for post-traumatic stress disorder.


Filed Under: clinical trials, Drug Discovery, Psychiatric/psychotropic drugs
Tagged With: Compass Pathways, Dr. George A. Mashour, Dr. Jennifer Miller, psilocybin, TRP-8802, TRP-8803, Tryp, Tryp Therapeutics, University of Florida, University of Michigan
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Janssen
Janssen’s company group chairman dishes on growth strategy
Curebase
Curebase raises $40 million in Series B funding round 

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50